Wie sind die Öffnungszeiten?

Montag 09:00 - 18:00 Dienstag 09:00 - 18:00 Mittwoch 09:00 - 18:00 Donnerstag 09:00 - 18:00 Freitag 09:00 - 18:00

Sciomics: Enabling precision medicine

Name: Sciomics: Enabling precision medicine
Address: Karl-Landsteiner-Str. 6, Neckargemünd, 69151, DE
Telephone: +4962214294830
Price range: £

Startseite
Deutschland
Neckargemünd
Sciomics: Enabling precision medicine

Anrufen Wegbeschreibung Website

Enabling Precision Medicine through innovative Protein Biomarker signatures.

Protein profiling plays an essential part in today’s biomedical research, striving to improve patients’ quality of life by using molecular signatures for diagnosis and treatment guidance. At Sciomics, we believe that our explorative proteomic and post-translational modification profiling platform enables true progress in precision medicine. Therefore, our internal development pipeline of innovative biomarker signatures for precision medicine is based on this powerful platform. In addition, we offer services based on our scioDiscover profiling platform and R&D collaborations for the discovery and validation of novel biomarkers, for drug target screening, the characterization of disease models, and for the analysis of pathway activity as well as mode-of-action analyses. What sets us apart is our team of scientific experts that takes pride in custom-tailoring every project and consulting clients throughout the project. Our full service ranges from discussing experimental designs to in-depth data analysis and a comprehensive study report. Fast and cost-efficient, Sciomics‘ powerful high-content, high-throughput antibody array platform delivers reliable results that can be easily translated into validation or clinical assays, thereby generating value and opening new avenues for biomarker discovery as well as preclinical drug discovery & development programs. Main applications of our platform are:
- identification and verification of protein biomarkers
- discovery of novel drug targets
- drug mode-of-action analysis
- analysis of pathway activity

19/02/2025

Wir stehen für 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻,
wir stehen für 𝗪𝗶𝘀𝘀𝗲𝗻𝘀𝗰𝗵𝗮𝗳𝘁,
wir stehen für 𝗗𝗲𝗺𝗼𝗸𝗿𝗮𝘁𝗶𝗲.

Innovation,
Wissenschaft und
Demokratie
sind bunt !

Wir lieben bunt !

Innovation,
Wissenschaft und
Demokratie
basieren auf Fakten.

Fakten sind die Basis unseres Tuns.

𝗡𝘂𝘁𝘇𝘁 𝗮𝘂𝗰𝗵 𝗶𝗵𝗿 𝗘𝘂𝗿𝗲 𝗦𝘁𝗶𝗺𝗺𝗲 𝗳ü𝗿 𝗱𝗶𝗲 𝗗𝗲𝗺𝗼𝗸𝗿𝗮𝘁𝗶𝗲 !

14/01/2025

👩‍🔬👨‍🔬 In collaboration with AbbVie we have taken another step to address the urgent need for reliable and sensitive 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝘀 𝗳𝗼𝗿 𝗻𝗲𝘂𝗿𝗼𝗱𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝘃𝗲 𝗱𝗶𝘀𝗼𝗿𝗱𝗲𝗿𝘀.

Our collaborative study analyzed protein levels of cerebrospinal fluid (CSF) and plasma samples from patients with Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. Using the 𝘀𝗰𝗶𝗼𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺, various differentially expressed proteins in comparison to healthy controls were identified, including:

• 𝗖𝗗𝟭𝟰: Elevated levels in CSF of patients with 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿’𝘀 𝗱𝗶𝘀𝗲𝗮𝘀𝗲
• 𝗢𝘀𝘁𝗲𝗼𝗽𝗼𝗻𝘁𝗶𝗻 (𝗢𝗣𝗡): Elevated levels in CSF of patients with 𝗣𝗮𝗿𝗸𝗶𝗻𝘀𝗼𝗻’𝘀 𝗱𝗶𝘀𝗲𝗮𝘀𝗲

🔬 These findings were validated using automated fluorescence-based 𝗦𝗶𝗺𝗽𝗹𝗲 𝗣𝗹𝗲𝘅𝗧𝗠 𝗶𝗺𝗺𝘂𝗻𝗼𝗮𝘀𝘀𝗮𝘆𝘀, demonstrating the strength of combining exploratory proteomics with targeted ligand-binding assays for biomarker discovery and validation.

At Sciomics, we are happy to contribute to the advancement of biomarker research for neurodegenerative diseases in collaboration with AbbVie.

📄 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝘀𝘁𝘂𝗱𝘆 𝗵𝗲𝗿𝗲:
Kenzelmann, A., Boch, C., Schmidt, R., Richter, M., Schulz, M. (2024). Exploration of Novel Biomarkers for Neurodegenerative Diseases Using Proteomic Analysis and Ligand-Binding Assays. Biomedicines, 12(12), 2794. https://doi.org/10.3390/biomedicines12122794

👉 https://www.mdpi.com/2227-9059/12/12/2794

Annalena Kenzelmann I Christina Boch I Ronny Schmidt I Mario Richter I Michael Schulz

19/12/2024

🎄✨ 𝗦𝗲𝗮𝘀𝗼𝗻’𝘀 𝗚𝗿𝗲𝗲𝘁𝗶𝗻𝗴𝘀 𝗳𝗿𝗼𝗺 𝗦𝗰𝗶𝗼𝗺𝗶𝗰𝘀 ✨🎄

As the year comes to an end, we at Sciomics want to take a moment to reflect on the incredible projects we have accomplished together in 2024. A great thank you to all our 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀 𝗮𝗻𝗱 𝗰𝘂𝘀𝘁𝗼𝗺𝗲𝗿𝘀 - your contribution and collaboration have been key to making this year so successful and memorable.

👩‍🔬 👨‍🔬 To celebrate this season, our team came together to decorate our Christmas tree and share a delightful Christmas dinner. These moments remind us of the joy that drives our journey.

🚀 We look forward to an exciting 2025 filled with inspiring projects, collaborations, innovations, and growth. 🚀

𝗙𝗿𝗼𝗺 𝗮𝗹𝗹 𝗼𝗳 𝘂𝘀 𝗮𝘁 𝗦𝗰𝗶𝗼𝗺𝗶𝗰𝘀, 𝘄𝗲 𝘄𝗶𝘀𝗵 𝘆𝗼𝘂 𝗮 𝗠𝗲𝗿𝗿𝘆 𝗖𝗵𝗿𝗶𝘀𝘁𝗺𝗮𝘀, 𝗛𝗮𝗽𝗽𝘆 𝗛𝗼𝗹𝗶𝗱𝗮𝘆𝘀, 𝗮𝗻𝗱 𝗮 𝗽𝗿𝗼𝘀𝗽𝗲𝗿𝗼𝘂𝘀 𝗡𝗲𝘄 𝗬𝗲𝗮𝗿! 🥂

21/11/2024

🌍 𝗪𝗵𝗮𝘁 𝗱𝗿𝗶𝘃𝗲𝘀 𝘁𝗵𝗲 𝗴𝗹𝗼𝗯𝗮𝗹 𝗳𝗶𝗴𝗵𝘁 𝗮𝗴𝗮𝗶𝗻𝘀𝘁 𝗽𝗮𝗻𝗰𝗿𝗲𝗮𝘁𝗶𝗰 𝗰𝗮𝗻𝗰𝗲𝗿? 💜

On this 𝗪𝗼𝗿𝗹𝗱 𝗣𝗮𝗻𝗰𝗿𝗲𝗮𝘁𝗶𝗰 𝗖𝗮𝗻𝗰𝗲𝗿 𝗗𝗮𝘆, the 𝗦𝗰𝗶𝗼𝗺𝗶𝗰𝘀 𝘁𝗲𝗮𝗺 𝗮𝗽𝗽𝗿𝗲𝗰𝗶𝗮𝘁𝗲𝘀 the dedication and efforts of the global research community in uncovering the molecular mechanisms behind one of the most challenging cancers to detect and treat.

Pancreatic cancer often presents late, making 𝗲𝗮𝗿𝗹𝘆 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 and 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 critical goals for the patients and research community. From studying its fundamental molecular mechanisms to advancing diagnostics and therapeutics, every discovery brings potential new avenues of treatment and better outcome to patients and their families.

🔬 At Sciomics, we are proud to support these efforts through our 𝗵𝗶𝗴𝗵-𝘁𝗵𝗿𝗼𝘂𝗴𝗵𝗽𝘂𝘁 𝗽𝗿𝗼𝘁𝗲𝗶𝗻 𝗮𝗻𝗱 𝗽𝗼𝘀𝘁-𝘁𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗺𝗼𝗱𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻 (𝗣𝗧𝗠) 𝗽𝗿𝗼𝗳𝗶𝗹𝗶𝗻𝗴 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺, enabling biomarker discovery and advancing Precision Medicine.

👩‍🔬 👨‍🔬 Let’s work together toward a better future for those affected by pancreatic cancer.

14/11/2024

🌍 𝗪𝗼𝗿𝗹𝗱 𝗗𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝗗𝗮𝘆 𝟮𝟬𝟮𝟰: 𝗕𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗕𝗮𝗿𝗿𝗶𝗲𝗿𝘀, 𝗕𝗿𝗶𝗱𝗴𝗶𝗻𝗴 𝗚𝗮𝗽𝘀 💙

On 𝗪𝗼𝗿𝗹𝗱 𝗗𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝗗𝗮𝘆, we at 𝗦𝗰𝗶𝗼𝗺𝗶𝗰𝘀 𝗚𝗺𝗯𝗛 reflect on the profound impact of diabetes research and our contributions toward advancing science for better patient outcomes. We work with partners from academia and biotech to discover 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝘀 and to understand the 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺𝘀 underlying diabetes and its complications, including its relationship with cancer, neurodegenerative diseases, and other metabolic diseases.

🔬 In recent years, the 𝗦𝗰𝗶𝗼𝗺𝗶𝗰𝘀 𝘁𝗲𝗮𝗺 contributed to a study titled "𝗖𝗵𝗮𝗻𝗴𝗲𝘀 𝗶𝗻 𝗽𝗿𝗼𝘁𝗲𝗶𝗻 𝗲𝘅𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻 𝗱𝘂𝗲 𝘁𝗼 𝗺𝗲𝘁𝗳𝗼𝗿𝗺𝗶𝗻 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗵𝘆𝗽𝗲𝗿𝗶𝗻𝘀𝘂𝗹𝗶𝗻𝗲𝗺𝗶𝗮 𝗶𝗻 𝗮 𝗵𝘂𝗺𝗮𝗻 𝗲𝗻𝗱𝗼𝗺𝗲𝘁𝗿𝗶𝗮𝗹 𝗰𝗮𝗻𝗰𝗲𝗿 𝗰𝗲𝗹𝗹 𝗹𝗶𝗻𝗲". This research explored how metformin, a commonly prescribed medication for type II diabetes mellitus, influences protein expression in cancer cells, particularly in the context of hyperinsulinemia – a condition commonly seen in diabetic patients.

👩‍🔬 👨‍🔬 Through our 𝘀𝗰𝗶𝗼𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 antibody microarray service, we helped to uncover key insights into how metformin may counteract some of the pro-cancerous effects induced by high insulin levels. These findings bring us closer to understanding how diabetes treatments can play a role not only in managing diabetes but also in preventing or treating associated conditions, such as endometrial cancer.

Carsten Lange | Amanda Machado Weber | Ronny Schmidt |Christoph Schröder | Thomas Strowitzki | Ariane Germeyer

23/10/2024

🌟 𝗢𝘂𝗿 𝗷𝗼𝘂𝗿𝗻𝗲𝘆 𝘁𝗼 𝗱𝗲𝘃𝗲𝗹𝗼𝗽 𝗮 𝗯𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝘁𝗼𝗼𝗹 𝗳𝗼𝗿 𝗔𝗰𝘂𝘁𝗲 𝗞𝗶𝗱𝗻𝗲𝘆 𝗜𝗻𝗷𝘂𝗿𝘆 (𝗔𝗞𝗜) 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝘀! 🌟

✈️ We are on our way to 𝗦𝗮𝗻 𝗗𝗶𝗲𝗴𝗼 for 𝗞𝗶𝗱𝗻𝗲𝘆 𝗪𝗲𝗲𝗸 𝟮𝟬𝟮𝟰! Our colleagues Anne Griesbeck and Christoph Schröder are excited to gain new insights and engage in discussions with the kidney research community.

👩‍🔬 👨‍🔬 At Sciomics, we have dedicated significant effort to identifying biomarkers for the early detection of 𝗔𝗰𝘂𝘁𝗲 𝗞𝗶𝗱𝗻𝗲𝘆 𝗜𝗻𝗷𝘂𝗿𝘆 (𝗔𝗞𝗜). During Kidney Week, we look forward to 𝗲𝘅𝗽𝗮𝗻𝗱𝗶𝗻𝗴 𝗼𝘂𝗿 𝗻𝗲𝘁𝘄𝗼𝗿𝗸 and finding 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀 to help develop a reliable diagnostic test that can detect this common complication 𝘁𝘄𝗼 𝗱𝗮𝘆𝘀 𝗲𝗮𝗿𝗹𝗶𝗲𝗿 than the current clinical gold standard.

🤝 If you are attending Kidney Week and would like to connect, please reach out to Anne and Christoph!

🌎 𝗦𝗮𝗳𝗲 𝘁𝗿𝗮𝘃𝗲𝗹𝘀 𝘁𝗼 𝗮𝗹𝗹 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝗻𝘁𝘀 𝗮𝗻𝗱 𝘄𝗲 𝗹𝗼𝗼𝗸 𝗳𝗼𝗿𝘄𝗮𝗿𝗱 𝘁𝗼 𝘀𝗲𝗲𝗶𝗻𝗴 𝘆𝗼𝘂 𝗶𝗻 𝗦𝗮𝗻 𝗗𝗶𝗲𝗴𝗼! 🌎

10/10/2024

🚀 𝗧𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗻𝗴 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗟𝗮𝗯 𝘁𝗼 𝘁𝗵𝗲 𝗖𝗹𝗶𝗻𝗶𝗰 🚀

Exciting day at the 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗜𝗻𝘃𝗲𝘀𝘁𝗶𝗴𝗮𝘁𝗼𝗿𝘀’ 𝗗𝗮𝘆 𝟮𝟬𝟮𝟰, organized by the BioRN Life Science Cluster Rhine-Neckar. Our colleagues Barbara Eberbach and Dr. Christoph Schröder just pitched our 𝗴𝗿𝗼𝘂𝗻𝗱𝗯𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 - a precise diagnostic test for 𝗔𝗰𝘂𝘁𝗲 𝗞𝗶𝗱𝗻𝗲𝘆 𝗜𝗻𝗷𝘂𝗿𝘆 (𝗔𝗞𝗜) that detects this common complication 𝘁𝘄𝗼 𝗱𝗮𝘆𝘀 𝗲𝗮𝗿𝗹𝗶𝗲𝗿 than the current clinical gold standard.

👩‍🔬 👨‍🔬 This diagnostic test is based on biomarkers identified through our 𝗦𝗰𝗶𝗼𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺, demonstrating the successful translation of microarray-based research into clinical application.

We are actively seeking 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀 to bring this innovative test to market and make a real difference in patient outcomes. Let's push innovation forward! 🤝

09/10/2024

🌟 𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗗𝗮𝘆 𝗮𝘁 𝘁𝗵𝗲 𝗕𝗶𝗼𝗥𝗡 𝗔𝗻𝗻𝘂𝗮𝗹 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝟮𝟬𝟮𝟰! 🌟

👩‍🔬 👨‍🔬 The Sciomics team is proud to participate in the BioRN Annual Conference 2024, hosted by the BioRN Life Science Cluster. Meet our colleagues Dr. Christoph Schröder and Ronny Schmidt at the new Heidelberg Congress Center.

🔬 This year’s focus on 𝗻𝗲𝘄 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗺𝗼𝗱𝗮𝗹𝗶𝘁𝗶𝗲𝘀 𝗶𝗻 𝗽𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗲𝗱 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 aligns perfectly with our mission to advance 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 and 𝗽𝗿𝗼𝘁𝗲𝗼𝗺𝗶𝗰𝘀. Christoph and Ronny are excited to gain new insights and exchange ideas, exploring how we can drive the future of personalized healthcare together.

We look forward to fostering meaningful collaborations with both new and longstanding partners! 🤝

22/08/2024

We are back from our social media summer break 🙂 , and what better way to recharge than with our summer company outing! ☀ Taking time off to connect with the team was the perfect way to gear up for the next “season”.🚀

We spent a fantastic day hiking through the scenic beauty of the Rhine-Neckar region 🏞 - A vibrant area known for its rich life sciences ecosystem. 🔬 After reaching our destination, we enjoyed a relaxing boat ride back and ended the day with a proper BBQ and refreshing drinks. ⛴

These moments remind us how important it is to take a step back, connect with each other, and appreciate the journey we are on together. 👩‍🔬 👨‍🔬

05/04/2024

This Sunday is World Health Day! 🌎 🔥 Health is not a privilege, it is a fundamental human right. But this right is increasingly under threat. Political conflict and environmental pollution threaten the health and safety of millions of people and claim lives. 🌏
This year's World Health Day theme, "My Health, My Right," was chosen to promote the right of everyone, everywhere, to access health services, education, and information, as well as safe drinking water, clean air, good nutrition, quality housing, decent working and environmental conditions, and freedom from discrimination. 🔥
Let's strive for equal access to health care, education, and safe living conditions! When we prioritize health as a right, we pave the way for a better, healthier future for all. 👨‍👩‍👧‍👦 🌍 ✨

April 7 marks the anniversary of the founding of WHO in 1948.

14/03/2024

Heute ist Welt-Nieren-Tag!

Lasst uns das Bewusstsein für die Bedeutung der Nierengesundheit und die lebenswichtige Rolle, die unsere Nieren dabei spielen, erhöhen. Wusstest Du, dass Nierenerkrankungen Millionen von Menschen weltweit betreffen?

Es ist Zeit, Maßnahmen zu ergreifen, um Nierenproblemen vorzubeugen, sie zu erkennen und zu behandeln. Der Welt-Nieren-Tag zielt darauf ab, das Bewusstsein für die Bedeutung sicherzustellen, dass Menschen mit Nierenerkrankungen einen gerechten Zugang zu angemessener Behandlung und Betreuung erhalten, um ihre Lebensqualität zu verbessern und den Fortschritt der Krankheit zu verzögern.

Um mehr über Nierenerkrankungen und die Kampagne zu erfahren, besuche bitte: www.worldkidneyday.org

Bei Sciomics: Enabling precision medicine sind wir stolz auf unsere hausinterne Forschung zu Akuter Nierenschädigung (AKI). AKI ist ein plötzlicher Verlust der Nierenfunktion, der oft als Komplikation anderer schwerwiegender medizinischer Zustände auftritt. Zum Beispiel tritt AKI häufig als Komplikation nach großen Operationen auf, kann aber auch durch Sepsis, Nebenwirkungen von Medikamenten oder Komorbiditäten verursacht werden.

Eine frühzeitige Erkennung und Intervention bei AKI ist entscheidend für Patienten: Sie kann den Umfang der Nierenschäden reduzieren und die Chance erhöhen, dass AKI reversibel ist. Unser scioAKI-Projekt hat vielversprechende frühzeitige Biomarker-Kombinationen für perioperative AKI mit einer sehr starken diagnostischen Leistung identifiziert. Basierend auf diesen Ergebnissen zielen wir darauf ab, einen zuverlässigen und einfach zu verwendenden Test für die frühzeitige Diagnose von AKI in einer klinischen Umgebung zu entwickeln.

Schließe Dich uns an, um das Bewusstsein zu verbreiten und für eine bessere Nierengesundheit auf der ganzen Welt zu werben!

World Kidney Day

14/03/2024

We are excited to participate in the first BioLabs European Investor Day in Paris! Europe’s top biotech startups and the most active European and international life science investors will come together on March 19th to advance medicine.

We are honored to present our contributions to the earlier and precise diagnosis of Acute Kidney Injury (AKI). Sciomics scioAKI project has identified promising early biomarker combinations for perioperative AKI with a very strong diagnostic performance.

Based on these results, a new spin-off will be dedicated to the development of a reliable and easy-to-use test for the early diagnosis of AKI in a clinical setting.

Saving kidneys, saving lives!

Adresse

Karl-Landsteiner-Str. 6
Neckargemünd
69151

Öffnungszeiten

Montag	09:00 - 18:00
Dienstag	09:00 - 18:00
Mittwoch	09:00 - 18:00
Donnerstag	09:00 - 18:00
Freitag	09:00 - 18:00

Telefon

+4962214294830

Website

http://www.sciomics.de/

Benachrichtigungen

Erfahren Sie als Erste/r von Neuigkeiten und Aktionen: Wir schicken Ihnen eine E-Mail, wenn Sciomics: Enabling precision medicine etwas veröffentlicht. Ihre E-Mail-Adresse wird für keinen anderen Zweck verwendet, und Sie können sich jederzeit abmelden.